# US 2020/0390833 A1 · Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390833 A1
- Document ID: US20200390833A1
- Status: Published application
- Kind: A1
- Application number: 16/976,952
- Filed: 2019-03-15
- Published: 2020-12-17
- Earliest claimed: 2018-03-15
- Assignees: University of Southern California
- Applicants: University of Southern California
- Inventors: Valter D. LONGO; Min WEI; Priya RANGAN
- Web page: https://patentgrep.com/patent/US20200390833A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23B 2/92: Freeze drying
- A23L 19/01: {Instant products; Powders; Flakes; Granules (A23L19/10 – A23L19/12 take precedence)}
- A23L 19/09: {Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks (A23L19/01, A23L19/10, A23L27/63 and A23L21/00 take precedence)}
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 35/745: Bifidobacteria
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61K 36/23: Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K 36/31: Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23B: PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.

## Claims

### Claim 1

A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease, the probiotic composition comprising:
a bacterial component selected from the group consisting of Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof to be administered for prevention and treatment of gastrointestinal autoimmune and/or inflammatory disease; and
a protective component that stabilizes the bacterial component.

### Claim 2 (depends on 1)

The probiotic composition of claim 1 wherein the bacterial component further comprises gut microbiota strains isolated from genera selected from the group consisting of Lactobacillus, Allobaculum, Bifidobacterium, and combinations thereof.

### Claim 3 (depends on 2)

The probiotic composition of claim 2 wherein each bacterial component is present in an amount from about 103 to about 1014 CFU/g of each bacterial component.

### Claim 4 (depends on 1)

The probiotic composition of claim 1 wherein the protect component is selected from the group consisting of protective carriers, protective coating, and protective encapsulants.

### Claim 5 (depends on 1)

The probiotic composition of claim 1 wherein the protective component is a room temperature liquid.

### Claim 6 (depends on 5)

The probiotic composition of claim 5 wherein the room temperature liquid. is an hydroxylated hydrocarbon carrier.

### Claim 7 (depends on 5)

The probiotic composition of claim 5 wherein the room temperature liquid. is a polyol.

### Claim 8 (depends on 1)

The probiotic composition of claim 1 wherein the protective component includes a stabilization agent that interacts with or encapsulates the bacterial component.

### Claim 9 (depends on 8)

The probiotic composition of claim 8 wherein the stabilization agent is selected from the group consisting of adonitol, betaine, carbohydrates (e.g., sugars), proteins, amino acids, mixtures of sugar and protein, gums and skim milk, and combinations thereof.

### Claim 10 (depends on 9)

The probiotic composition of claim 9 wherein the stabilization agent is dissolved or dispersed in a room temperature liquid.

### Claim 11 (depends on 1)

The probiotic composition of claim 1 wherein the protective component encapsulates the bacterial component.

### Claim 12 (depends on 11)

The probiotic composition of claim 11 wherein the bacterial component is encapsulated by spray drying, fluidized bed drying and vacuum drying.

### Claim 13 (depends on 11)

The probiotic composition of claim 11 wherein the protective component includes an encapsulating agent selected from the group consisting of maltodextrins, skim milk, reconstituted skim milk, casein, soybean protein, trehalose, maltodextrin, and combinations thereof.

### Claim 14 (depends on 1)

The probiotic composition of claim 1 wherein the bacterial component includes a combination of Bacteroides acidifaciens and Bifidobacterium choerinum such that the Bifidobacterium choerinum enhances probiotic activity of Bacteroides acidifaciens.

### Claim 15 (depends on 1)

The probiotic composition of claim 1 further comprising an additive selected from the group consisting of any suitable adjuvants, excipients, additives, additional therapeutic agents, bioavailability enhancers, side-effect suppressing components, diluents, buffers, flavoring agents, binders, preservatives or other ingredients and combinations thereof.

### Claim 16 (depends on 1)

The probiotic composition of claim 1 incorporated into a capsule.

### Claim 17

A method for preventing or treating gastrointestinal autoimmune and/or inflammatory disease, the method comprising:
identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering; and
administering a fasting mimicking diet for a first predetermined time period.

### Claim 18 (depends on 17)

The method of claim 17 wherein the fasting mimicking diet provides at most 50% of a subject's normal caloric intake and at least 5% of the subject's normal caloric intake.

### Claim 19 (depends on 17)

The method of claim 17 wherein the fasting mimicking diet provides at most 1500 kcal/day and at least 800 kcal/day.

### Claim 20 (depends on 17)

The method of claim 17 wherein the fasting mimicking diet is the PROLON® diet.

### Claim 21 (depends on 17)

The method of claim 17 wherein the fasting mimicking diet is administered for 2 or more cycles.

### Claim 22 (depends on 17)

The method of claim 17 wherein a probiotic composition is administered to the subject during the first predetermined time period, the probiotic composition comprising:
a bacterial component selected from the group consisting of Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof; and
a protective component that stabilizes the bacterial component.

### Claim 23 (depends on 22)

The method of claim 22 wherein the bacterial component further comprises gut microbiota strains isolated from genera selected from the group consisting of Lactobacillus, Allobaculum, Bifidobacterium, and combinations thereof.

### Claim 24 (depends on 23)

The method of claim 23 wherein each bacterial component is present in an amount from about 103 to about 1014 CFU/g of each bacterial component.

### Claim 25 (depends on 22)

The method of claim 22 wherein the protect component is selected from the group consisting of protective carriers, protective coating, and protective encapsulants.

### Claim 26

A dietary supplement comprising:
a powdered vegetable mixture of beets, carrots, collard, spinach, kale, mushroom, tomato, and optionally nettle leaf, the powdered vegetable mixture being dehydrated to form a dried vegetable powder.

### Claim 27 (depends on 26)

The dietary supplement of claim 26 being desiccated by freeze-drying.

### Claim 28 (depends on 26)

The dietary supplement of claim 26 wherein dried vegetable powder incudes 5 to 20 weight percent of powder formed from beets, 5 to 20 weight percent of powder formed from carrots, 5 to 20 weight percent collard, 5 to 20 weight percent of powder formed from spinach, 5 to 20 weight percent of powder formed from kale, 5 to 20 weight percent mushroom, 5 to 20 weight percent of powder formed from tomato, and 0 to 20 weight percent of powder formed from nettle leaf.
